Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
MR Harrison, BA Costello, NA Bhavsar… - Cancer, 2021 - Wiley Online Library
Background Systemic therapy (ST) can be deferred in patients who have metastatic renal
cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients …
cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients …
[HTML][HTML] Treatment of advanced renal cell carcinoma: immunotherapies have demonstrated overall survival benefits while targeted therapies have not
O Hemminki, N Perlis, J Bjorklund, A Finelli… - European urology open …, 2020 - Elsevier
Context Current guidelines suggest several targeted therapies (TTs) and immunotherapies
(ITs) in the treatment of advanced or metastatic renal cell carcinoma (mRCC). Ideal …
(ITs) in the treatment of advanced or metastatic renal cell carcinoma (mRCC). Ideal …
Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study
S Demasure, I Spriet, PR Debruyne, A Laenen… - Acta …, 2022 - Taylor & Francis
Background Only a few recent phase III trials with targeted therapies or immune checkpoint
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …
Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
K Hemminki, A Försti, A Hemminki, B Ljungberg… - PLoS …, 2021 - journals.plos.org
Global survival studies have shown favorable development in renal cell carcinoma (RCC)
treatment but few studies have considered extended periods or covered populations for …
treatment but few studies have considered extended periods or covered populations for …
[HTML][HTML] Clinical T1a renal cell carcinoma, not always a harmless disease—A national register study
T Almdalal, P Sundqvist, U Harmenberg… - European Urology Open …, 2022 - Elsevier
Background T1a renal cell carcinoma (RCC) is typically considered a curable disease,
irrespective of the choice of local treatment modality. Objective To identify factors associated …
irrespective of the choice of local treatment modality. Objective To identify factors associated …
Survival and Functional Outcomes after Surgical Treatment for Spinal Metastasis in patients with a short life expectancy
SJ Park, CH Ma, CS Lee, CY Jeon, TS Shin… - Journal of clinical …, 2022 - mdpi.com
This study aimed to analyze the survival and functional outcome after surgery in spinal
metastasis patients with a short life expectancy and to compare the baseline characteristics …
metastasis patients with a short life expectancy and to compare the baseline characteristics …
[HTML][HTML] Changes in treatment reality and survival of patients with advanced clear cell renal cell carcinoma–analyses from the german clinical RCC-registry
PJ Goebell, M Staehler, L Müller, A Nusch… - Clinical Genitourinary …, 2018 - Elsevier
Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC)
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …
Comparative survival associated with use of targeted vs nontargeted therapy in medicare patients with metastatic renal cell carcinoma
P Li, J Jahnke, AR Pettit, YN Wong… - JAMA Network …, 2019 - jamanetwork.com
Importance Targeted therapies for advanced renal cell carcinoma (RCC) have shown
increased tolerability and survival advantages over older treatments in clinical trials, but …
increased tolerability and survival advantages over older treatments in clinical trials, but …
Inflammatory response markers and survival prediction in patients with renal cell carcinoma
A Mountzias, J Hultdin, J Hlodan… - … journal of urology, 2022 - Taylor & Francis
Introduction Many factors influence the clinical course of patients with renal cell carcinoma
(RCC). The most commonly used prognostic indicators are TNM stage, tumor size and RCC …
(RCC). The most commonly used prognostic indicators are TNM stage, tumor size and RCC …
Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a …
B Ljungberg, P Sundqvist, P Lindblad… - … journal of urology, 2020 - Taylor & Francis
Background Recently, the CARMENA and SURTIME studies, suggested that upfront
cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and …
cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and …